MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, Chatzikou et al. assessed the economic impact of AI-driven diagnostic systems developed within the EU-funded HosmartAI project, focusing on cardiology, obstetrics, and gastroenterology.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of November 03rd, we plan to work on 21 projects. Review the complete list of planned activities in this post.

In November 2025, NHS England released a final summary of core changes between OPCS-4.10 and OPCS-4.11, a procedure coding classification updated every three years. Multiple changes were implemented, including 572 new four-character (subcategory) codes in various fields, such as cardiovascular, peripheral vascular, diagnostic imaging, endoscopy, gastroenterology, urology and nephrology, obstetrics and gynecology, men’s health, neurology and neurosurgery, pulmonology, orthopedics, spine, interventional radiology, and radiotherapy. OPCS-4.11 is expected to take effect on April 1, 2026.

In October 2025, the Swedish Dental and Pharmaceutical Benefits Agency (TLV) launched two new thematic horizon scans focusing on cancer care. The scans aim to identify innovative medical technologies that may be evaluated within the national Orderly introduction framework for medical technologies. Stakeholders, including industry representatives, are invited to submit proposals by November 30, 2025.

In September-October 2025, the Dutch Organization for Health Research and Development (ZonMw) opened the submission of applications for another two rounds of the Medical Specialist Care and Research (MedZO) program. The applications deadline for “Line 1: Appropriate and efficient care - Round 2” is December 2, 2025; for “Preparatory implementation activities Round 2 - specialist medical care” - December 9, 2025.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Collin et al. conducted a scoping review of digital health interventions designed for adolescents and young adults implemented between 2017 and 2023.

In October 2025, the National Institute for Health and Care Research (NIHR) in England released four Med Tech-related assessments in its HTA Journal, which concerned tumor profiling tests in early breast cancer, remote monitoring of heart failure in people with cardiac implantable electronic devices, microstructural scaffolds in symptomatic defects of the knee, as well as rapid tests for antifungal stewardship in the ICU.

The French National Authority for Health (HAS) released new recommendations on the registration of medical devices and medical aids in the List of Reimbursable Products and Services (LPPR) following the October 2025 meetings of the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDiMTS). Seven favourable opinions were issued concerning add-on reimbursement for medical devices in the neuromodulation and interventional radiology fields.

In October 2025, the National Institute for Health and Care Excellence (NICE) published one new Early Value Assessment on AI technologies for the detection of vertebral fragility fractures and two new Interventional Procedures Guidances on venoarterial extracorporeal membrane oxygenation (VA-ECMO) in refractory cardiac arrest and severe acute heart failure.

On October 20, 2025, Genomic Medicine Sweden (GMS) announced the launch of five strategic development projects aimed at extending access to advanced diagnostics nationwide. The projects will focus on updating national GMS gene panel (big NGS panel for solid tumors), liquid biopsies, cell-free tumor DNA (ctDNA) for diagnosis and follow-up of metastatic breast cancer, gene panels for hepatopancreatobiliary (HPB) cancer, and improving diagnosis of sarcoma.

On October 17, 2025, the European Commission adopted an implementing regulation that sets detailed procedural rules for Joint Clinical Assessments of medical devices and in vitro diagnostics under the HTA Regulation, which entered into force on 12 January 2025.

The MTRC team, including Director Oleg Borisenko and Deputy Reimbursement Lead Julia Mazur, will be attending the ISPOR meeting in Glasgow, Scotland on 9-12 November.